Who is sponsoring NCT03672747?

NCT03672747 is sponsored by University of Nebraska.

What drugs are being tested in NCT03672747?

Interventions in NCT03672747: transcranial direct-current stimulation (tDCS).

What condition does NCT03672747 study?

NCT03672747 studies Brain Function.

Is NCT03672747 still recruiting?

NCT03672747 is currently completed. Last updated 31 July 2024.

Are results published for NCT03672747?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-07-31 · How we verify

NCT03672747

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Modulation of Spontaneous Cortical Activity by tDCS: BRAIN Initiative I

Completed NA Results posted Last updated 31 July 2024

What this trial tests

NA trial testing transcranial direct-current stimulation (tDCS) in Brain Function in 133 participants. Completed in 31 May 2023.

Timeline

20 February 2019

Primary endpoint
14 October 2022

31 May 2023

Quick facts

Lead sponsor	University of Nebraska
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	133
Start date	20 February 2019
Primary completion	14 October 2022
Estimated completion	31 May 2023
Sites	1 location across United States

Drugs / interventions tested

transcranial direct-current stimulation (tDCS)

Conditions studied

Brain Function — all drugs for Brain Function →

Sponsor

University of Nebraska

Who can join

Adults 19 to 72, any sex, with Brain Function. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Behavioral Performance (Accuracy) on Cognitive Tests of Perceptual Processing Primary · During the 90 minutes following stimulation

Do participants perform better in terms of accuracy following tDCS on behavioral measures of perceptual processing.

Group	Value	95% CI
Anodal Stimulation	97	± 1.26
Cathodal Stimulation	98	± 1.05
Sham Stimulation (Placebo)	98	± .94

The Power of Spontaneous Alpha Activity as Quantified by MEG Imaging Secondary · During the 90 minutes following stimulation

Does spontaneous alpha (9-13 Hz) power, as measured by MEG, get stronger following tDCS. Spontaneous activity refers to the level of background neural activity and is typically divided into frequency bands (e.g., alpha, gamma) that reflect the number of cycles per second. The outcome measure unit is nano-amperes square (nA\^2) since source-resolved MEG measures reflect electric current strength and not voltage units as in electroencephalography (EEG). The square is necessary since we examined power, which is the square of amplitude in the frequency domain. The unit is also commonly expressed a

Group	Value	95% CI
Anodal Stimulation	23.26	± 3.06
Cathodal Stimulation	15.88	± 2.18
Sham Stimulation (Placebo)	17.02	± 2.46

The Power of Oscillatory Alpha Activity as Quantified by MEG Imaging Secondary · During the 90 minutes following stimulation

Does oscillatory alpha neural activity, as measured by MEG, get stronger following tDCS. Oscillatory activity refers band-limited increases or decreases in the power of neural activity, relative to baseline, in response to a stimulus.

Group	Value	95% CI
Anodal Stimulation	-27.34	± 3.18
Cathodal Stimulation	-26.10	± 3.03
Sham Stimulation (Placebo)	-30.88	± 5.11

Behavioral Performance (Reaction Time) on Cognitive Tests of Perceptual Processing Primary · During the 90 minutes following stimulation

Do participants perform better in terms of reaction time following tDCS on behavioral measures of perceptual processing.

Group	Value	95% CI
Anodal Stimulation	713	± 67
Cathodal Stimulation	708	± 58
Sham Stimulation (Placebo)	724	± 52

The Power of Spontaneous Gamma Activity as Quantified by MEG Imaging Secondary · During the 90 minutes following stimulation

Does spontaneous gamma (45-80 Hz) power, as measured by MEG, get stronger following tDCS. Spontaneous activity refers to the level of background neural activity and is typically divided into frequency bands (e.g., alpha, gamma) that reflect the number of cycles per second. The outcome measure unit is nano-amperes square (nA\^2) since source-resolved MEG measures reflect electric current strength and not voltage units as in electroencephalography (EEG). The square is necessary since we examined power, which is the square of amplitude in the frequency domain. The unit is also commonly expressed

Group	Value	95% CI
Anodal Stimulation	3.46	± 1.74
Cathodal Stimulation	3.30	± 1.89
Sham Stimulation (Placebo)	2.43	± 1.55

The Power of Oscillatory Gamma Activity as Quantified by MEG Imaging Secondary · During the 90 minutes following stimulation

Does oscillatory gamma neural activity, as measured by MEG, get stronger following tDCS. Oscillatory activity refers band-limited increases or decreases in the power of neural activity, relative to baseline, in response to a stimulus.

Group	Value	95% CI
Anodal Stimulation	10.78	± 2.74
Cathodal Stimulation	6.35	± 1.98
Sham Stimulation (Placebo)	6.28	± 1.87

Sponsor's own description

This study will determine whether transcranial direct current stimulation (tDCS) can be used alter the amplitude of spontaneous neural activity, and thereby modulate cognitive function in healthy adults

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Brain Function

Currently open trials in the same condition.

NCT07392905 — Food Intake-Related Brain and Metabolic Responses in Obesity · NA · recruiting
NCT06910293 — Whole-Brain Dynamics in the Natural Menstrual Cycle vs. an Ovarian Stimulated Cycle: Impact of Hormonal Fluctuations on · recruiting
NCT06921980 — Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia · recruiting
NCT06826287 — 7T Anatomo-functional Characterization of Structures in the Action Observation Network · recruiting
NCT05912556 — Brain Response to an Intervention Using Guided, At-Home Technology for the Mind · NA · active not recruiting

Other University of Nebraska trials

Trials by the same sponsor.

NCT07507006 — Feasibility Study of the Flash-Sole: A Wearable Midsole With Soft Actuators for Walking Assistance · NA · not yet recruiting
NCT07517705 — MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma · NA · not yet recruiting
NCT07506993 — Inflammation in Clear Aligners With and Without Attachments · not yet recruiting
NCT07207850 — Parents Helping Parents for Youth Vaping Cessation · NA · not yet recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03672747 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nebraska
Last refreshed: 31 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03672747.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing